このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

完全な膝関節形成術の修正のための術前ホールフード植物ベースの繊維スムージー

2026年9月25日 更新者:Hospital for Special Surgery, New York

炎症と術後の痛みに対する膝関節置換手術全体を修正する2週間前に、毎日のホールフード植物ベースのスムージー利用の影響

This study aims to assess the feasibility of a 2-week dietary whole-food smoothie intervention and compare outcomes between two groups: patients that integrated a daily whole food plant-based smoothie into their diet for two weeks prior to surgery, and a control group of revision TKA patients that made no nutritional changes to their diet prior to surgery. The main research questions are:

  1. Among patients planned for elective TKA revision surgery, what is the feasibility of a 2-week dietary intervention implemented 2 weeks prior to surgery? [Outcomes will be compliance, noted barriers and/or facilitators, satisfaction with diet]
  2. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will reduce inflammation -measured in plasma levels of IL-6 and CRP- at POD0, POD1, POD2, POD3, and 6 Weeks Post-operative as compared to 1) baseline (prior to dietary intervention initiation) and 2) control patients who did not make changes in their diet prior to surgery.
  3. Determine if the implementation of a daily whole food plant-based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in quantifiable changes in the gut microbiome composition -measured via fecal samples- as compared to control patients who did not make changes in their diet prior to surgery.
  4. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in improved immediate postoperative pain -measured through numeric rating scale (NRS) pain scores- and opioid use -measured in morphine milligram equivalents (MME)- as compared to control patients.
  5. Compare patient satisfaction and adoption of nutritional behavioral changes in patients implementing a whole food plant-based smoothie 2 weeks prior to TKA revision surgery to patients undergoing the same surgery but did not me pre-surgery dietary changes.

The researcher's primary outcome is measuring feasibility and patient compliance with smoothie consumption. Secondarily, the investigators are interested in measuring if the preoperative smoothie can alter the gut microbiome and decrease systemic inflammation, leading to lowered post-operative pain and opioid use.

調査の概要

詳細な説明

This study aims to assess the feasibility of a 2-week dietary whole-food smoothie intervention and compare outcomes between two groups: patients that integrated a daily whole food plant-based smoothie into their diet for two weeks prior to surgery, and a control group of revision TKA patients that made no nutritional changes to their diet prior to surgery. The main research questions are:

  1. Among patients planned for elective TKA revision surgery, what is the feasibility of a 2-week dietary intervention implemented 2 weeks prior to surgery? [Outcomes will be compliance, noted barriers and/or facilitators, satisfaction with diet]
  2. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will reduce inflammation -measured in plasma levels of IL-6 and CRP- at POD0, POD1, POD2, POD3, and 6 Weeks Post-operative as compared to 1) baseline (prior to dietary intervention initiation) and 2) control patients who did not make changes in their diet prior to surgery.
  3. Determine if the implementation of a daily whole food plant-based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in quantifiable changes in the gut microbiome composition -measured via fecal samples- as compared to control patients who did not make changes in their diet prior to surgery.
  4. Determine if the implementation of a daily whole food plant- based smoothie dietary supplement 2 weeks prior to TKA revision surgery will result in improved immediate postoperative pain -measured through numeric rating scale (NRS) pain scores- and opioid use -measured in morphine milligram equivalents (MME)- as compared to control patients.
  5. Compare patient satisfaction and adoption of nutritional behavioral changes in patients implementing a whole food plant-based smoothie 2 weeks prior to TKA revision surgery to patients undergoing the same surgery but did not me pre-surgery dietary changes.

Participants will be randomly assigned to consume the whole food plant-based smoothie intervention daily for the two weeks leading up to surgery, or to have no preoperative diet intervention (control group).

The researcher's primary outcome is measuring feasibility and patient compliance with smoothie consumption. Secondarily, the investigators are interested in measuring if the preoperative smoothie can alter the gut microbiome and decrease systemic inflammation, leading to lowered post-operative pain and opioid use.

研究の種類

介入

入学 (推定)

24

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Pa Thor, PhD
  • 電話番号:646-797-8535
  • メール:thorp@hss.edu

研究連絡先のバックアップ

  • 名前:Mia Zonies, BS
  • 電話番号:646-714-6849
  • メール:zoniesm@hss.edu

研究場所

    • New York
      • New York、New York、アメリカ、10021
        • 募集
        • HSS Main Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion:

  • Scheduled for revision TKA at HSS with participating surgeons; not as a result of infection or trauma and all components (tibial and femoral) needing replacement
  • Age between 40 and 85
  • Diagnosed with osteoarthritis
  • Diagnosed with 2+ modifiable chronic lifestyle diseases: Type 2 DM, CVD (such as CAD, heart disease, stroke, HTN), stress, anxiety, depression, ADHD, metabolic syndrome, certain types of cancer (such as breast, colorectal, lung, prostate), Alzheimer's disease, vascular cognitive impairment, CKD, RA, asthma, chronic pain conditions (such as chronic back pain and osteoarthritis), fibromyalgia, migraines, COPD (Steiber 2011, Grant 2014)
  • ASA Class 1 ('normal' healthy patient) or 2 (patient with mild systemic disease and no functional limitations; the diseases the patient has are well controlled) or 3 (patient with severe systemic disease that results in functional limitations)
  • Ability to understand written and spoken English
  • Willing to complete entire pre-operative and post-operative work up in NYC, main campus site and/or HSS Ambulatory Care Center
  • Willing to follow a 2-week smoothie supplement, including willingness to purchase ingredients and have access to a blender for preparation

Exclusion:

  • Age >85 years or <40 years
  • Revision due to infection or trauma
  • ASA class 4 (patient with severe systemic disease that is a constant threat to life)
  • Not interested or unable to provide informed consent
  • Unstable weight (>5kg weight change in the past 3 months, documented in Epic)
  • Active infection, flare-up of seasonal allergies, or physical trauma (all can alter CRP)
  • Medication changes the month leading up to surgery
  • Specifically medications altering inflammation: Statins (Ridker 2008), steroids (Boumpas et al., Ann Intern Med 1993; glucocorticoid cytokine modulation research.), DMARDS/biologics/immunosuppressants (Clinical rheumatology guidelines, biologic RCTs (e.g., TNF inhibitors, IL-6 inhibitors), Colchicine (Tardif et al., N Engl J Med 2019; colchicine cardiovascular inflammation studies.), hormone replacement therapies (Ridker et al., JAMA 1999; OCs and CRP meta-analyses.), new psychiatric medications (Miller & Raison, Nat Rev Immunol 2016; psychotropic-inflammation associations.)
  • BMI >40 kg/m2
  • Food intolerance/allergy/sensitivity to ingredients suggested for smoothies
  • History of IBD (and IBD medication)
  • History of bariatric surgery
  • History of cancer
  • History of thyroid disease
  • History of or current drug abuse
  • Pregnancy
  • Current smoker
  • Any patient with an electronic cardiac implant

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Group 1 No Smoothie

This group will make no changes to their pre-operative diet and will not consume the smoothie leading up to their TKA revision surgery.

実験的:Group 2 Smoothie

This group will receive the "Green Smoothie Guide" from the American College of Lifestyle Medicine which they will use to prepare a daily smoothie for the 14 days leading up to their total knee arthroplasty revision surgery. No other changes will be made to their pre-operative diet.

The "Green Smoothie Guide" from the American College of Lifestyle Medicine contains guidelines for a 6-step smoothie to include whole and high fiber foods.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Feasibility Measured in Terms of Compliance
時間枠:Daily for 14 days pre-operative

Compliance is measured as number of days in the two-week intervention timeframe that patients reported having consumed the smoothie. The investigators will conduct fourteen daily phone calls to assess yes/no smoothie intake and ingredients used. Informed by nutrition compliance in the literature, the investigators will apply an 80% threshold for compliance rate which translates to roughly 11/14 days. The compliance range is 0%-100% or 0-14 days with 100% or 14 days indicating higher smoothie compliance and a more favorable outcome.

Daily for 14 days pre-operative
Feasibility Measured in Terms of Noted Barriers/Facilitators
時間枠:Day 0

Noted barriers/facilitators are open-ended questions in unstructured free text format. A feedback form will be sent to participants, and feedback and suggestions will be recorded by the investigators.

Day 0
Feasibility Measured in Terms of Satisfaction with Diet
時間枠:Baseline and 6 weeks post-operative

The quantification of satisfaction with diet using the verified Diet Satisfaction Scale with 28 questions. Individual questions are scored on a scale of 1-5 with a higher score indicating higher diet satisfaction and a more favorable outcome. Scores from each question will be compiled into a total score for the questionnaire.

Baseline and 6 weeks post-operative

二次結果の測定

結果測定
メジャーの説明
時間枠
Inflammation and Pain Control: C-Reactive Protein
時間枠:Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op

Inflammation and pain control are quantified by biological markers of inflammation such as C-reactive protein found in the blood. C-reactive protein is produced in the liver, and its levels rise in response to inflammation. A normal range of C-reactive protein is less than 0.3mg/dL and is a more favorable outcome than an elevated level of C-reactive protein.

Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op
Inflammation and Pain Control: Interleukin 6
時間枠:Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op

Inflammation and pain control are quantified by biological markers of inflammation such as the pro-inflammatory cytokine, interleukin 6, found in the blood. An elevated amount of Interleukin 6, above 15pg/mL, is indicative of increased inflammatory response in the body and is less favorable outcome.

Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op
Inflammation and Pain Control: Microbiome Composition
時間枠:Baseline, 4 Days Pre-op, 2 Days Pre-op

Inflammation and pain control are quantified firstly by biological markers of inflammation such as microbiome composition. Participants will complete three self-administered stool sample collections and ship their samples to Mount Sinai Laboratory. Mount Sinai will conduct raw 16S rRNA sequencing to show alpha and beta bacteria diversity. Higher diversity 4 days pre-op and 2 days pre-op relative to baseline is indicative of a more successful intervention and a more favorable outcome.

Baseline, 4 Days Pre-op, 2 Days Pre-op
Inflammation and Pain Control- Numerical Rating Scales
時間枠:Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op

Inflammation and pain control are quantified firstly by markers of acute pain/analgesia which are measured by Numerical Rating Scales (NRS) of pain. Participants will be asked questions about their knee pain on a scale of 0-10 where higher scores are indicative of increased pain and a less favorable outcome.

Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op
Inflammation and Pain Control: Opioid Intake
時間枠:Postoperatively; 0-24 hours, 24-48 hours, and 48-72 hours

Inflammation and pain control are quantified by markers of acute pain/analgesia such as opioid intake. Opioid intake will be recorded from participants' medical charts while they are under care at HSS Main Hospital. Opioid intake will be measured in morphine milligram equivalents (MME) with a lower opioid intake being more favorable.

Postoperatively; 0-24 hours, 24-48 hours, and 48-72 hours
Diet Quantification
時間枠:Baseline, Day 0, and 6 weeks post-op.

Diet will be quantified using Diet ID Inc.'s online software, a validated tool, which measures diet quality, caloric intake, and nutrient intake. After participants go through the Diet ID survey, the Diet ID platform will calculate a "Nutrition Score" which will be the recorded value of nutrition. The scores will be reported on a scale of 1-10 with higher scores indicating "better" nutrition and a more favorable outcome.

Baseline, Day 0, and 6 weeks post-op.
BIA Measurements: Phase Angle
時間枠:Baseline, Day 0, and 6 weeks post-op.

Bioelectrical Impedance Analysis (BIA) produces a measurement of phase angle (PhA) which measures the water distribution among intracellular and extracellular space. Phase angle is measured in degrees with 6.5-7.5 degrees being described as a healthy range and lower degrees being less favorable.

Baseline, Day 0, and 6 weeks post-op.
BIA Measurements: Fat-Free Mass (Index)
時間枠:Baseline, Day 0, and 6 weeks post-op.

Bioelectrical Impedance Analysis (BIA) produces a measurement of fat-free mass (FFM) which is a measurement of the total body weight excluding fat. BIA testing produces a fat-free mass weight in kg which is divided by the total kg of the participant to produce a percentage of fat-free mass. For men, a healthy range for a fat-free mass percentage is ~78%-87%, and for women, a healthy range is ~67%-75%. The fat-free mass index measurement can also be calculated using the measurement of fat-free mass relative to height.

Baseline, Day 0, and 6 weeks post-op.
BIA Measurements: Extracellular Water
時間枠:Baseline, Day 0, and 6 weeks post-op.

Bioelectrical Impedance Analysis (BIA) can produce measurements of extracellular water (ECW) which is the water outside of the cells.

Baseline, Day 0, and 6 weeks post-op.
BIA Measurements: Extracellular Water, Total Body Water, and Ratio ECW/TBW
時間枠:Baseline, Day 0, and 6 weeks post-op.

Bioelectrical Impedance Analysis (BIA) can produce measurements of Extracellular Water (ECW)--the fluid outside of the cells--and Total Body Water (TBW). Then, a ratio of extracellular water to total body water (ECW/TBW) can be calculated with a normal range for this ratio being 0.360-0.390. A higher value for this ratio is indicative of a less favorable outcome.

Baseline, Day 0, and 6 weeks post-op.
PROMIS-Global 10
時間枠:Baseline, Day 0, 6 weeks post-op, and 6 months post-op.

The PROMIS-Global 10 is a validated 10-item questionnaire to evaluate health in relation to quality of life. Questions are rated on a scale of 1-5 with a higher score being indicative of higher health and a more favorable outcome. Scores for all questions will be added up to calculate a total score.

Baseline, Day 0, 6 weeks post-op, and 6 months post-op.
Range of Motion
時間枠:Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op

Angle of knee movement in degrees as recorded during all standard of care visits. Measurement points include: the internist physician during pre-surgical screening, the surgeon on Day 0, physical therapy on Days 1-3, the surgeon during the 6-week post-operative follow-up visit.

Baseline, Day 0, Day 1, Day 2, Day 3, 6 weeks post-op
Frailty
時間枠:Baseline

The 5-Item frailty index is a standardized, comorbidity-based risk stratification tool used to predict adverse events.

Baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Erica Tafuro, MD、Hospital for Special Surgery, New York

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月28日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2025年3月13日

QC基準を満たした最初の提出物

2025年3月19日

最初の投稿 (実際)

2025年3月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2024-2396

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する